Physician profile
Amanda Wallace
NPI 1275104796
$5,567.41
in general payments reported to CMS, 2019-2025
23 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.21 · 2022: $427 · 2023: $1,505 · 2024: $1,773 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,955 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.72 |
| Education | $170.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $870.31 | 2022-2025 | Biktarvy |
| Viiv Healthcare Company | $730.18 | 2022-2025 | Cabenuva, Apretude, Rukobia |
| Abbvie INC. | $608.56 | 2023-2025 | |
| Melinta Therapeutics, LLC | $596.05 | 2022-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Merck Sharp & Dohme LLC | $489.58 | 2022-2025 | Dificid, Zerbaxa, Pifeltro |
| Astellas Pharma US INC | $417.31 | 2024-2025 | Veozah, Cresemba |
| Paratek Pharmaceuticals, INC. | $398.64 | 2022-2025 | Nuzyra |
| Insmed, INC. | $346.53 | 2022-2025 | Arikayce, Brinsupri |
| La Jolla Pharmaceutical Company | $219.68 | 2024-2025 | Xerava, Zevtera, Giapreza |
| Aimmune Therapeutics, INC. | $193.87 | 2024-2025 | Vowst, Zenpep |
| Ferring Pharmaceuticals INC. | $183.38 | 2023-2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $130.10 | 2022-2024 | Lokelma |
| Shionogi INC | $105.03 | 2023-2024 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $65.35 | 2025 | |
| Electromed, INC. | $42.81 | 2025 | Smartvest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38.65 | 2022-2023 | Symtuza |
| Nalu Medical, INC. | $23.58 | 2022 | |
| Smith+Nephew, INC. | $21.51 | 2025 | Collagenase Santyl |
| Pfizer INC. | $19.45 | 2024 | |
| Zimmer Biomet Holdings, INC. | $18.61 | 2022 | |
| Si-Bone, INC. | $17.68 | 2022 | |
| Convatec INC. | $15.34 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $15.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.